Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer

HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. It is a clinically aggressive subtype; however, the introduction of targeted therapies has greatly improved survival rates. At JADPRO Live 2022, presenters discussed recent updates to clinical practice for HER2-positive m...

Descripción completa

Detalles Bibliográficos
Autores principales: Beasley, Marcie, Daniel, Brooke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184838/
https://www.ncbi.nlm.nih.gov/pubmed/37197725
http://dx.doi.org/10.6004/jadpro.2023.14.3.13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184838/
https://www.ncbi.nlm.nih.gov/pubmed/37197725
http://dx.doi.org/10.6004/jadpro.2023.14.3.13

Ejemplares similares